Semaglutide activates one metabolic receptor (GLP-1). Tirzepatide activates two (GIP and GLP-1). The research question is whether the second receptor produces meaningfully better outcomes.

The answer, based on head-to-head clinical data, is yes — but the why is still being worked out.

The story of dual agonism is really the story of GIP — because GLP-1 agonism was already well-established. The question was: what does adding GIP do?

Adipose tissue signaling. GIP receptors are expressed directly on adipocytes. Research by Samms et al. showed that GIP receptor agonism produced insulin sensitization in adipose tissue that was independent of body weight changes — meaning GIP didn't just help lose fat, it made the remaining fat tissue function more healthily. This effect is absent with GLP-1-only agonism.¹

Potential anti-nausea effects. GIP has established anti-emetic properties. Some researchers hypothesize that GIP co-activation partially offsets the nausea caused by GLP-1 receptor stimulation — potentially explaining why tirzepatide produces greater weight loss without proportionally greater GI side effects.

Bone preservation. GIP stimulates osteoblast activity. Rapid weight loss from any intervention can reduce bone mineral density. GIP's bone-building signal may partially protect against this — a hypothesis being studied in long-term trials.²

Enhanced insulin secretion. Both GIP and GLP-1 stimulate glucose-dependent insulin release, but through different intracellular pathways. The combination may produce a more robust and sustained insulin response than either alone.

SURPASS-2: Head-to-Head in Type 2 Diabetes

This trial directly compared tirzepatide (5, 10, 15 mg) against semaglutide (1 mg) in patients with type 2 diabetes. Results published in the New England Journal of Medicine showed tirzepatide outperformed semaglutide on every primary endpoint at every dose level tested.³

The highest tirzepatide dose produced a 2.30% HbA1c reduction vs 1.55% for semaglutide — a clinically meaningful difference. Weight loss was also significantly greater with tirzepatide across all doses.

SURMOUNT vs STEP: Obesity Comparisons

While not a direct head-to-head trial, comparing the tirzepatide SURMOUNT program against the semaglutide STEP program provides the most relevant data for the obesity research question.

STEP-1 (semaglutide 2.4 mg): Mean weight loss ~15% at 68 weeks. SURMOUNT-1 (tirzepatide 15 mg): Mean weight loss ~20.9% at 72 weeks.⁴

The ~6 percentage point difference is substantial — it represents approximately 15 additional pounds of weight loss for a 250-pound individual. More strikingly, 36% of participants on the highest tirzepatide dose achieved ≥25% body weight reduction, compared to approximately 12% with semaglutide.

OSYRIS GLP-3 (R) represents the next step in this progression — a triple GIP/GLP-1/glucagon agonist in the retatrutide class. Phase 2 data showed 24.2% mean weight loss, exceeding tirzepatide's results.⁵

The glucagon receptor adds hepatic fat oxidation and increased energy expenditure — effects absent from both single and dual agonists. The pattern is clear: each additional receptor target has produced incremental metabolic effects in clinical data so far. Whether this trend continues with further receptor additions, or whether complexity eventually produces diminishing returns, is the central open question.

The OSYRIS catalog with GLP-1 (S), GLP-2 (T), and GLP-3 (R) gives researchers the tools to study this progression systematically in preclinical models.

GLP-1 (S) if your protocol requires a clean single-receptor reference, if you're studying GLP-1-specific biology in isolation, or if you need a baseline against which to measure dual/triple agonism.

GLP-2 (T) if your protocol studies dual agonism, GIP receptor biology, adipose tissue signaling, or the incremental effects of adding GIP to GLP-1.

Both if your protocol is a comparative study examining the contribution of each receptor to metabolic outcomes.